Claritas Pharmaceuticals Inc V.CLAS.H

The smart ones did not sell their shares..

[ChiefBronco]

big money on the way for kalytera investors. Hold on its gonna be a wild ride, let the good times roll

[RiskyBiz928]

I only held on because I'm at a loss. So when do you think it'll start trading again? I'd like to get the F. out. :-(

[Bigginvestor]

yea when would that be like to get the hell out!!

[Chritters]

Don't come here and Jinxing this stock, Go back to pumping FSD Pharma.

[LI4VESTREAMSD]

This post has been removed in accordance with Community Policy

[Oenophile]

Jinx this stock? LMAO 

[Oenophile]

Might Kalytera have enough data to release their GvHD therapeutic in the EU with a post market trial? Phase 3 only required 25 patients. They pretty much approve anything in Europe - look at NeoVasc's device for refractory angina. EU approved 8 years ago, FDA advisory committee completely trashed their presentation/data yesterday. Might also try compassionate use in the US? Trying to be

[Matteo1234]

Agreed. Any hint of nitrous oxide assist covid-19 through the motions and then Shabangles. Pappy goes BOOM.?lol?pool?p.

[Scotty]

We don't own GVHD anymore, we defaulted and gave it back to Talent. It's half the reason most of us ar pissed.

[Oenophile]

I know they defaulted, but didn't they need shareholder approval to give away the Israeli subsidiary and phase 2 data?

[Oenophile]

I just quickly looked at md&a, they need to vote first. I think the milestone could be renegotiated (againt) but with reasonable terms, if not I wouldn't hand over any data all. That data cost shareholders millions. Let Talent sue - I guarantee they won't. It's a slim chance, but only hope. Barda isn't going to fund R107.

[Dude51]

Barda is not going to fund R-107? Based on? Your mouth piece.

[Scotty]

I agree it's our only hope to save our investments, but there's too many bag holders who think R-107 will save KLY and won't vote to deny giving back GVHD, it would destroy our balance sheet not to and probably end the company. Odds are it's going to RS then dilute to fund Salz's research, rinse and repeat until R-107 is adequately funded, then a new phase 1 drug will come

[Oenophile]

Probably true, Scotty, though I can't see anyone brokering another financing for this company for R107. Bay street can't sell this to their clients. No chance Barda funds this with so many promising therapeutics/prophylaxes in pre-clinical development that haven't been funded. If Salzman thought he could get funding Radikal would have kept it for themselves. The fact acquisition wasn